Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Speciality: Nephrology
Description:
A warm welcome to all the medical professionals in this exciting session on evolving science in the space of CKD.
The global prevalence of CKD is substantial with profound implications, healthcare costs, and outcomes. The risk of morbidity and mortality rises sharply as CKD progresses. The vast majority of larger-scale trials in CKD have focussed on Type 2 Diabetes populations.
SGLT2 inhibition has a number of potential direct and downstream effects which may result in beneficial effects on kidney function. SGLT2i CVOTs have consistently shown a reduction in renal endpoints. DAPA-CKD builds upon the evidence for Dapagliflozin in preventing hHF and worsening renal disease in DECLARE and reducing the risk of worsening HF and CV death in DAPA-HF.
Therefore, listen to the webinar, grab the shared knowledge, and follow HiDoc for more such exciting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Patients face high out-of-pocket costs after incident cancer diagnosis
2.
In a study, immune detection of oral cancers is linked to obesity.
3.
Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.
4.
Every cancer is different because of how evolution causes drug resistance and why various cancers require various treatments.
5.
Common intracellular toxin could help fight leukemia
1.
Understanding Sickle Cell Anemia: Causes, Symptoms, and Treatment Options
2.
The Latest Research on Chronic Granulomatous Disease and Promising New Treatments
3.
Advancing Oncology Careers with Education, Workflow Tools, and Clinical Resources
4.
Florinef: Understanding Its Uses and Side Effects
5.
Uncovering the Subtle Signs of Leukemia: A Guide to Early Detection
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
2.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
3.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge